Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Image source: Getty Images. Comparing Eli Lilly and Viking Therapeutics. Every market leader started somewhere, and Eli Lilly's history of innovation spans 149 years since its founding in 1876.

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday. Rich Smith, The Motley Fool. May 2, 2025 at 11:55 AM. Copied; ...

Eli Lilly's (LLY) $1.3B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both companies.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Within the pharmaceuticals industry in particular, shares of Eli Lilly (LLY 1.33%), Novo Nordisk (NVO-1.50%), and Viking Therapeutics (VKTX-0.23%) are all looking to close out the week strong.

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday May 02, 2025 — 11:55 am EDT Written by Rich Smith for The Motley Fool -> ...